Triaryl Compounds Stimulating Beta-Cell Mass via Telomerase
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diabetes lack a cure and effective methods to stimulate or increase pancreatic beta-cell mass, which is crucial for managing insulin levels and glucose regulation.
Innovation Solution
The use of specific tri-phenyl compounds that activate or enhance telomerase expression or activity, leading to the stimulation or increase of pancreatic beta-cell mass in diabetic subjects, thereby improving glucose tolerance and reducing insulin resistance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional diabetes treatments are used, then blood glucose levels can be managed, but pancreatic beta-cell mass cannot be stimulated or increased
Solution Approach 1:
The patent uses telomerase activators as intermediary substances to indirectly stimulate pancreatic beta-cell mass. Instead of directly targeting beta cells, the compounds activate telomerase, which then promotes beta-cell proliferation and survival through telomere maintenance, resolving the contradiction by introducing a mediating biological pathway
Solution Approach 2:
The patent changes the biological parameter of telomerase activity to achieve beta-cell mass increase. By administering telomerase activators that modify the telomerase activity parameter, the treatment indirectly increases beta-cell mass, transforming the approach from direct beta-cell targeting to parameter-mediated stimulation
2Reliability
If no new treatment approaches are developed, then current diabetes management continues, but a cure remains unavailable
Solution Approach 1:
The patent extracts and targets a specific biological mechanism (telomerase activity) that is distinct from conventional diabetes treatments. By isolating and activating this specific pathway, the invention creates a novel cure mechanism that differs fundamentally from existing insulin-based or glucose-lowering therapies, thereby achieving a cure while maintaining manageable complexity
3Quantity of substance
If telomerase activity is not activated, then pancreatic beta-cell mass remains stable, but glucose tolerance deteriorates in diabetic subjects
Solution Approach 1:
The patent applies preliminary action by activating telomerase before significant beta-cell loss occurs or to prevent further deterioration. The telomerase activators work prophylactically to maintain telomere length and prevent beta-cell apoptosis, thereby preserving beta-cell mass and preventing glucose tolerance impairment before it worsens
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds significantly reduce blood glucose levels, increase pancreatic beta-cell mass, and improve glucose tolerance, demonstrating therapeutic potential in managing diabetes and its complications.
Implementation Method 1
the compound can activate or enhance telomerase expression or activity
Data Source
Figure 1A~1B
Figure 2A
Figure 2B
AI summary
The present invention is directed to use of a series of tri-aryl compounds and compositions comprising the same for the treatment of diabetes and disease conditions arising as a consequence of the same.